Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Gains from Investment Securities (2016 - 2023)

Historic Gains from Investment Securities for Spyre Therapeutics (SYRE) over the last 9 years, with Q2 2023 value amounting to $63.4 million.

  • Spyre Therapeutics' Gains from Investment Securities rose 1468261.42% to $63.4 million in Q2 2023 from the same period last year, while for Mar 2024 it was $8000.0, marking a year-over-year increase of 10134.91%. This contributed to the annual value of -$915000.0 for FY2023, which is 10903.52% down from last year.
  • According to the latest figures from Q2 2023, Spyre Therapeutics' Gains from Investment Securities is $63.4 million, which was up 1468261.42% from $8000.0 recorded in Q1 2023.
  • Spyre Therapeutics' 5-year Gains from Investment Securities high stood at $63.4 million for Q2 2023, and its period low was -$836000.0 during Q4 2022.
  • Its 5-year average for Gains from Investment Securities is $3.8 million, with a median of $8000.0 in 2020.
  • As far as peak fluctuations go, Spyre Therapeutics' Gains from Investment Securities crashed by 59467.46% in 2022, and later soared by 1468261.42% in 2023.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Gains from Investment Securities stood at $7000.0 in 2019, then fell by 28.57% to $5000.0 in 2020, then soared by 3280.0% to $169000.0 in 2021, then crashed by 594.67% to -$836000.0 in 2022, then skyrocketed by 7685.82% to $63.4 million in 2023.
  • Its Gains from Investment Securities stands at $63.4 million for Q2 2023, versus $8000.0 for Q1 2023 and -$836000.0 for Q4 2022.